• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study
CONCLUSION: Among patients with AF, apixaban use was associated with lower risk for GIB and similar rates of ischemic stroke or systemic embolism, ICH, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban. This finding was consistent for patients aged 80 years or older and those with chronic kidney disease, who are often underrepresented in clinical trials.PRIMARY FUNDING SOURCE: None.PMID:36315950 | DOI:10.7326/M22-0511
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Wallis C Y Lau Carmen Olga Torre Kenneth K C Man Henry Morgan Stewart Sarah Seager Mui Van Zandt Christian Reich Jing Li Jack Brewster Gregory Y H Lip Aroon D Hingorani Li Wei Ian C K Wong Source Type: research

Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis
CONCLUSION: Although LAAO could be an alternative to anticoagulants for stroke prevention in patients with AF and high bleeding risk, the overall benefit from LAAO depends on the combination of stroke and bleeding risks in individual patients. These results suggest the need for a sufficiently low stroke risk for LAAO to be beneficial. The authors believe that these results could improve shared decision making when selecting patients for LAAO.PRIMARY FUNDING SOURCE: None.PMID:35969865 | DOI:10.7326/M21-4653
Source: Annals of Internal Medicine - August 15, 2022 Category: Internal Medicine Authors: Derek S Chew Ke Zhou Sean D Pokorney David B Matchar Sreekanth Vemulapalli Larry A Allen Kevin P Jackson Zainab Samad Manesh R Patel James V Freeman Jonathan P Piccini Source Type: research

Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study
CONCLUSION: For older adults with AF, apixaban was associated with lower rates of adverse events across all frailty levels. Dabigatran and rivaroxaban were associated with lower event rates only among nonfrail patients.PRIMARY FUNDING SOURCE: National Institute on Aging.PMID:34280330 | DOI:10.7326/M20-7141
Source: Annals of Internal Medicine - July 19, 2021 Category: Internal Medicine Authors: Dae Hyun Kim Ajinkya Pawar Joshua J Gagne Lily G Bessette Hemin Lee Robert J Glynn Sebastian Schneeweiss Source Type: research

Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study
CONCLUSION: In this comparative effectiveness study using practice-based claims data, patients with valvular AF who were new users of DOACs had lower risks for ischemic stroke or systemic embolism and major bleeding than new users of warfarin. These data may be used to guide risk-benefit discussions regarding anticoagulant choices for patients with valvular AF.PRIMARY FUNDING SOURCE: None.PMID:33780291 | DOI:10.7326/M20-6194
Source: Annals of Internal Medicine - March 29, 2021 Category: Internal Medicine Authors: Ghadeer K Dawwas Eric Dietrich Adam Cuker Geoffrey D Barnes Charles E Leonard James D Lewis Source Type: research

Pages: 1  2